When doctors treat cancer with immune checkpoint inhibitors, they are trying to jumpstart the body's natural defenses. However, not every patient responds the same way. New research highlights how two major factors—age and sex—shape the internal environment where these drugs work.
For older patients, the body undergoes a process called immunosenescence. This is a natural decline in the function of immune cells like T and B lymphocytes. Additionally, a state called inflammaging creates a setting that can make it harder for the immune system to attack tumors. For patients of different sexes, factors like hormones, genetics, and gut bacteria create unique differences in how the body handles immune responses.
While these findings are based on the underlying mechanisms of the body rather than specific clinical trial results, they offer a path forward. Understanding these differences could help doctors create more personalized plans. By tailoring treatments to a person's specific age and sex, doctors may be able to improve how effectively cancer drugs work for every individual.
